Siglec-6:慢性淋巴细胞白血病CAR-T治疗的新靶点
本研究评估了靶向Siglec-6的CAR-T细胞作为慢性淋巴细胞白血病(CLL)新型疗法的潜力。基于来自经异基因造血干细胞移植治愈的CLL患者的全人源抗Siglec-6抗体JML1序列,作者构建了Siglec-6特异性CAR-T细胞,并在体外和异种移植小鼠模型中证实其能特异性靶向CLL细胞。短铰链区可增强对高表达Siglec-6靶细胞的活性,但对低表达CLL细胞的靶向作用相似。
要点
- Siglec-6在造血干细胞中不表达,mRNA和蛋白检测高度局限于胎盘和其他组织的免疫细胞。
- 基于全人源抗Siglec-6抗体JML1序列的CAR-T细胞在体外和异种移植小鼠模型中特异性靶向CLL细胞。
- 短铰链区可增强CAR-T细胞对高表达Siglec-6靶细胞的活性,但对低表达CLL细胞的靶向作用相似。
核心结论
- 本研究鉴定了一种针对CLL的新型CAR-T细胞疗法,并确立Siglec-6作为免疫治疗的潜在靶点。
研究设计与样本
- 临床前研究:构建Siglec-6特异性CAR-T细胞,在体外和异种移植小鼠模型中进行功能验证。
主要发现
- SIGLEC6 mRNA和Siglec-6蛋白检测高度局限于胎盘和其他组织的免疫细胞,在造血干细胞中不表达。
- 基于JML1序列的Siglec-6 CAR-T细胞在体外和异种移植小鼠模型中特异性靶向CLL细胞。
- 短铰链区增加CAR-T细胞对高表达Siglec-6靶细胞的活性,但对低表达CLL细胞的靶向作用相似。
临床怎么用
- Siglec-6可作为CLL CAR-T治疗的潜在新靶点,短铰链区设计可能优化对高表达靶细胞的活性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The only current curative treatment for chronic lymphocytic leukemia (CLL) is allogenic hematopoietic stem cell transplantation. Chimeric antigen receptor treatment targeting CD19 for CLL achieved some complete responses, suggesting the need for alternative or combinational therapies to achieve a more robust response. In this work, we evaluated CAR-T cells specific for Siglec-6, an antigen expressed in CLL, as a novel CAR-T cell treatment for CLL. We found that detection of SIGLEC6 mRNA and Siglec-6 protein is highly restricted to placenta and immune cells in other tissues and it is not expressed in hematopoietic stem cells. We generated CAR-T cells specific for Siglec-6 based on the sequence of the fully human anti-Siglec-6 antibody (JML1), which was identified in a CLL patient that was cured after allo-hematopoietic stem cell transplantation (alloHSCT), and observed that it specifically targeted CLL cells in vitro and in a xenograft mouse model. Interestingly, a short hinge region increased the activity of CAR-T cells to target cells expressing higher Siglec-6 levels but similarly targeted CLL cells expressing lower Siglec-6 levels in vitro and in vivo. Our results identify a novel CAR-T cell therapy for CLL and establish Siglec-6 as a possible target for immunotherapy.
引用
- Kovalovsky D, Yoon JH, Cyr MG, et al. Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia. Leukemia. 2021. PMID: 33633313. doi:10.1038/s41375-021-01188-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。